The highly selective RET inhibitor pralsetinib was well-tolerated and demonstrated robust, durable responses in patients with RET fusion-positive cancers regardless of tumor type, according to results from the international ...
Aug 12, 2022
0
36
A study in Denver is trying to determine whether a history of concussions increases a person's odds of developing cognitive or psychological symptoms of long COVID, and, if so, whether that points to new ways to treat the ...
Aug 9, 2022
0
5
The U.S. Food and Drug Administration has approved Enhertu (am-trastuzumab-deruxtecan-nxki), an intravenous infusion treatment for patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-low ...
Aug 9, 2022
0
20
The dense, diverse collection of bacteria and other microorganisms that begin colonizing the human gastrointestinal tract from birth—collectively called the gut microbiome—is known to influence digestion and immune responses. ...
Aug 3, 2022
0
3
When our cells process the oxygen we breathe and the food we eat every day in order to survive, they generate potentially toxic by-products popularly known as "free radicals." Some of these molecules perform functions essential ...
Jul 20, 2022
0
21
For patients with stage III or IV Hodgkin lymphoma, brentuximab vedotin is associated with a survival advantage, according to a study published online July 13 in the New England Journal of Medicine.
Jul 14, 2022
0
1
A Phase II clinical trial of poziotinib for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 mutations, led by researchers at The University of Texas MD Anderson Cancer Center, found ...
Jul 11, 2022
0
6
The addition of procarbazine, lomustine, and vincristine (PCV) chemotherapy to radiation therapy (RT) was shown to lengthen both disease control and survival relative to RT alone as first-line therapy following surgery on ...
Jun 28, 2022
0
36
Results from the NRG Oncology phase III clinical trial NRG GOG-0212 indicated that treating women who received complete clinical response (CCR) after first-line platinum-taxane therapy for advanced ovarian, peritoneal, or ...
Jun 28, 2022
0
24
For patients with AIDS-related lymphoma (ARL), hypoalbuminemia predicts inferior outcome, according to a study published online June 18 in Infectious Agents and Cancer.
Jun 24, 2022
0
66
